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Abstract A rapid and sensitive UPLC/Q–TOF–MS
method has been established for analysis of the constituents
in rat serum after oral administration of Fufang Zhenzhu
Tiaozhi (FTZ) capsule, an effective compound prescription
for treating hyperlipidemia in the clinic. The UPLC/MS
information of samples was obtained ﬁrst in FTZ prepa-
ration and FTZ-treated rat serum. Mass spectra were
acquired in both negative and positive ion modes. Thirty-
six constituents in rat serum after oral administration of
FTZ were detected, including the alkaloids, ginsenosides,
pentacyclic triterpenes, and their metabolites. These
chemicals were identiﬁed based on the retention time and
mass spectrometry data with those of authentic standards or
comparison of the literatures reports. Twenty-seven pro-
totype components originated from FTZ and nine were the
metabolites of the FTZ constituents. These results shed
light on the potential active constituents of the complex
traditional Chinese medicinal formulas.
Keywords UPLC/Q–TOF–MS  Serum pharmacology 
Metabolite  Fufang Zhenzhu Tiaozhi capsule
Introduction
Fufang Zhenzhu Tiaozhi (FTZ) capsule, the patentable
Chinese herbal medicine prescription, including Rhizoma
Coptidis, Radix Salvia Miltiorrhiza, Radix Notoginseng,
Fructus Ligustri Lucidi, Herba Cirsii Jeponici, Cortex
Eucommiae, Fructus Citri Sarcodactylis and Radix Atrac-
tylodes Macrocephala. FTZ has been prescribed for
12 years by virtue of the potential to regulate abnormal lipid
metabolism for treatment of dyslipidemia, atherosclerosis,
and related disease [1, 2]. Clinical practice on more than
3,000 dyslipidemic patients demonstrated that FTZ is very
safe and less harmful side effects [3, 4]. Giving FTZ not
only markedly decrease the levels serum total cholesterol,
glycerinate and low-density lipoprotein cholesterol while
raising high-density lipoprotein cholesterol, but also
improves hepatic tissue pathologic states, and prevents
atherosclerosis [5, 6].
At present, hundreds of constituents have been identi-
ﬁed, respectively and systematically, from the herbs that
compose FTZ [7]. Constituents such as oleanolic acid,
salvianolic acid A, salvianolic acid B, notoginsenoside R1,
ginsenoside Rb1, ginsenoside Rg1, berberine, palmatine
and jateorhizine have been experimentally veriﬁed [8, 9].
However, it remains unclear as to which constituents are
responsible for the lipid-modulating functions of the drug;
furthermore, there has been no integrated study of the
constituents of the formula which is not simply a blend of
the individual herbs but an integrated prescription.
Serum pharmacochemistry, which is an experimental
technique focusing on the analysis of serum samples
obtained after dosing, is based on the hypothesis that most
effective constituents need to be absorbed into the blood to
elicit activities after administration of traditional Chinese
medicines (TCMs), and the components absorbed and
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order to identify the in vivo active forms from TCM for-
mulas [10–14]. On the other hand, the rapid development
of analytical techniques, such as UPLC coupled with
HDMS technique in recent years provide a powerful tool
for qualitative and quantitative analysis of complicated
samples such as TCMs [15, 16].
The present study examined the constituents of rat
serum after oral administration of FTZ using combined
UPLC/Q-TOF-MS/MS. From a comprehensive analysis
of a FTZ preparation, rat serum collected from FTZ-treated
group and control group, 27 prototype components, and
nine metabolites originating from FTZ were identiﬁed. To
the best of our knowledge, this is the ﬁrst systematical
study on identifying the possible effective constituents in
FTZ. The information will guide us to explore the mech-
anism under the lipid-modulating effect of FTZ in the
following investigation.
Table 1 Structures of the Rhizoma Coptidis constituents identiﬁed in FTZ preparation and serum samples from FTZ-treated rats
Type Substituent group Name of constituent MW Observed
N
OR1
OR2
OR4
R3O
R5
R6
R1=R2=R3=R4=CH3,R5=H,
R6=OH
Hydroxyl-palmatine 368 In serum and in
preparation
R1?R2=CH2,R 3=H,
R4=CH3,R 5=R6=H
Thalifendine 322 In serum and in
preparation
R1=H, R2=R3=R4=CH3,
R5=R6=H
Columbamine 338 In serum and in
preparation
R1=R2=CH3,R 3?R4=CH2,
R5=R6=H
Epiberberine 336 In serum and in
preparation
R1?R2=R3?R4=CH2,
R5=R6=H
Coptisine 320 In serum and in
preparation
R1=CH3,R 2=H,
R3=R4=CH3,R 5=R6=H
Jatrorrhizine 338 In serum and in
preparation
R1?R2=CH2,R 3=CH3,
R4=H, R5=R6=H
Berberrubine 322 In serum and in
preparation
R1=R2=R3=R4=CH3,
R5=R6=H
Palmatine 352 In serum and in
preparation
R1?R2=CH2,R 3=R4=CH3,
R5=R6=H
Berberine 336 In serum and in
preparation
R1=R2=R3=R4=CH3,
R5=CH3,R 6=H
Dehydrocorydaline 366 In serum and in
preparation
R1?R2=CH2,R 3=R4=CH3,
R5=CH3,R 6=H
13-Methylberberine 350 In serum and in
preparation
R1=R2=R3=R4=CH3,
R5=CH2CH3,R 6=H
13-Ethyl-5,6-dihydro-2,3,9,10-
tetramethoxy-
dibenzo[a,g]quinolizinium
380 In preparation
only
R1=CH3,R 2=H,
R3=R4=CH3,R 5=CH3,
R6=H
Dehydrocorybulbine 352 In preparation
only
R1=CH3,R 2=GlcUA,
R3=R4=CH3,R 5=R6=H
Jatrorrhizine 3-O-b-D-glucuronide 514 In preparation
only
N
O
OH
HO
O
Magnoﬂorine 342 In serum only
In serum and in preparation: the constituent was observed both in FTZ-treated serum and FTZ preparation, in preparation only: the constituent
was only observed in FTZ preparation, in serum only: the constituent was only observed in FTZ-treated serum
MW molecular weight
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123Experimental
Chemicals and Materials
Authentic standards such as chloramphenicol, danshensu,
protocatechuic acid, protocatechuic aldehyde, salidroside,
rosmarinic acid, salvianolic acid B, specnuezhenide,
salvianolic acid A, jatrorrhizine, notoginsenoside R1,
palmatine, berberine, ginsenoside Rg1, ginsenoside Re, 5,7-
dimethoxycoumarin, ginsenoside Rb1, cryptotanshinone,
tanshinone IIA, and oleanolic acid were purchased from the
National Institute for the Control of Pharmaceutical and
Biological Products (Beijing, P. R. China). Acetonitrile was
of HPLC grade (Merck, Darmstadt, Germany). HPLC grade
methanol was provided by Honeywell International Inc.
(Burdick and Jackson, Muskegon, MI, USA). Phosphoric
acid and acetic acid glacial were of HPLC grade and pur-
chased from TianJin Chemical Reagents Development
Center (TianJin, China). Ultrapure water for the preparation
of samples and mobile phase was prepared with PURELAB
Ultra GE MK2 water system (ELGA, High Wycombe, UK).
Other reagents were of analytical grade. FTZ capsules were
prepared by the Institute of Materia Medica, Guangdong
Pharmaceutical University (batch number 20090607). Eight
comprised crude herbs were purchased from Zhixin Chinese
Herbal Medicine Co., Ltd. (Guangzhou, China) and all
the herbs were authenticated by Professor Shu-Yuan
Li (Guangdong Pharmaceutical University). A voucher
specimen was deposited in the Institute of Traditional
Chinese Medicine, Guangdong Pharmaceutical University,
Guangzhou, P. R. China.
Instrumentation and Analytical Conditions
The Waters AcQuity
TM Ultra Performance LC system
(Waters Corporation, Milford, USA) was equipped with
quaternary pump, vacuum degasser, a cooling autosampler,
and a diode-array detector. A UPLC
TM BEH C18 column
(50 9 2.1 mm, 1.7 lm) was utilized for separation with
the column temperature at 30 C. A binary gradient elution
was adopted with mobile phase consisting of (A) 0.25%
acetic acid glacial and 10 mM ammonium acetate in water
and (B) acetonitrile: 0-1.6 min, B 2-5%; 1.6-7.6 min, B
5-20%; 7.6-9.6 min, B 20%; 9.6-14.6 min, B 20-35%;
14.6-17.6 min, B 35-80%; 17.6-18 min, B 80-100%;
18-18.4 min, B 100%. The ﬂow rate was set at
Table 2 Structures of the Radix Notoginseng constituents identiﬁed in FTZ preparation and serum samples from FTZ-treated rats
Type Substituent group Name of constituent MW Observed
R1
R2
OH
H
R3 R1=OH, R2=OGlc(2–1)Xyl, R3=OGlc Notoginsenoside R1 932 In serum and in
preparation
R1=OH, R2=OGlc, R3=OGlc Ginsenoside Rg1 800 In serum and in
preparation
R1=OH, R2=OGlc(2–1)Rha,
R3=OGlc
Ginsenoside Re 946 In preparation only
R1=OH, R2=OGlc, R3=OH Ginsenoside Rh1 638 In serum and in
preparation
R1=OH, R2=OH, R3=OGlc Ginsenoside F1 638 In serum and in
preparation
R1=OGlc(2–1)Glc, R2=H,
R3=OGlc(6–1)Glc
Ginsenoside Rb1 1108 In serum and in
preparation
R1=OGlc(2–1)Glc, R2=H, R3=OGlc Ginsenoside Rd 946 In serum and in
preparation
R1=OH, R2=OH, R3=OH Protopanaxatriol 476 In serum only
R1=OGlc(2–1)Glc, R2=H, R3=OH Ginsenoside Rg3 784 In serum only
HO
R1
OH
H
R2
OH
R1=OGlc, R2=OH 25-Hydroxy-
ginsenoside Rh1
656 In serum only
R1=OH, R2=OGlc 25-Hydroxy-
ginsenoside F1
656 In serum only
In serum and in preparation: the constituent was observed both in FTZ-treated serum and FTZ preparation, in preparation only: the constituent
was only observed in FTZ preparation, in serum only: the constituent was only observed in FTZ-treated serum
MW molecular weight
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123Table 3 Structures of the Fructus Ligustri Lucidi constituents identiﬁed in FTZ preparation and serum samples from FTZ-treated rats
Type Substituent group Name of constituent MW Observed
O
OCH3 O
CH2COOCH3
OH
OGlc
10-Hydroxyoleoside
dimethyl ester
434 In serum and in
preparation
OH
GlcO
Salidroside 300 In serum and in
preparation
HO
HO O
O
H3CO O
OH
O
Oleuropeine aglycone 378 In preparation
only
HO
HO O
O
H3CO O
O
OGlc
 
Oleuropeine 540 In preparation
only
HO
H3CO
O
O
OGlc
OCH3
(?)-Pinoresinol-O-b-D-
glucopyranoside
520 In preparation
only
OH
OCH3
GlcO
Coniferin 342 In preparation
only
R3 R4
R1
COOH
R2
R5
R6
R1=OH, R2=OH,
R3=R4=CH3,R 5=R6=H
Masilinic acid 472 In serum and in
preparation
R1=CH3COO, R2=H,
R3=CH3,
R4=H, R5=CH3,R 6=OH Pomolic acid acetate 514 In serum and in
preparation
R1=OH, R2=H,
R3=R4=CH3,R 5=R6=H
Oleanolic acid 456 In serum and in
preparation
O
OGlc
O OCH3
O
O
O
OH
OH
OH
O
R
R=OH Specnuezhenide 686 In preparation
only
114 X. Zhong et al.
1230.40 mL min
-1. The autosampler was conditioned at 4 C,
and the injection volume was 10 lL.
The instrument Waters Micromass Q–TOF–micro
TM
(Waters Co., UK) was equipped with the Lock Spray and
ESI interface operating in both positive ion mode and
negative ion mode, and with MassLynx data analysis
software. The capillary voltage was set at 3 kV; the cone
voltage was set at 30 V for both positive ionization mode
and negative ionization mode. The ion source temperature
was set at 100 C and desolvation temperature at 350 C.
Nitrogen and argon were used for cone and collision gases,
respectively. The cone and desolvation gas ﬂows were 60
and 600 L h
-1, respectively. The mass spectrometric data
was collected in full scan mode with the mass range of
m/z 100–1,500, using independent reference lock-mass ions
via the Lock Spray interface to ensure mass accuracy and
reproducibility. The solution of chloramphenicol was used
as lock-mass, with an [M?H]
? ion of m/z 345.0021 and an
[M-H]
- ion of m/z 321.0045. The MS/MS analysis was
performed using a variable collision energy (20–50 eV),
which was optimized for each individual constituent. The
Lock Spray frequency was set at 10 s. Acquity UPLC/
Q–TOF micro system was operated using MassLynx 4.1
software (Waters Co., USA). The accurate mass and
composition for the precursor and fragment ions were
calculated by MassLynx 4.1.
Animals
Ten male Sprague–Dawley rats (body weight 200 ± 20 g)
were obtained from the Medical Experimental Animal
Center of Guangdong Province (Foshan, China). Animals
were housed under standard conditions of temperature,
humidity and light with food (laboratory rodent chow) and
water provided ad libitum and were acclimated in the
laboratory for at least 1 week prior to experiment. Before
administration, the animals were fasted overnight with free
access of water. All experimental protocols have been
approved by Institutional Animal Ethics Committee of
Guangdong Pharmaceutical University (GDPUIAEC
No.200902), and are also in a compliance with national and
international guidelines of animal welfare (NIH Guide for
the Care and Use of Laboratory Animals, NIH publication
No. 85-23, 1985).
Sample Preparation
Preparation of FTZ Extract
The preparation of FTZ extract from eight constituent
herbs was consistent with the protocol described previously
[1], and as follows: Radix Salvia Miltiorrhiza (50 g), Radix
Atractylodes Macrocephala (60 g), Fructus Citri Sarco-
dactylis (50 g), Cortex Eucommiae (40 g), and Herba
Cirsii Jeponici (30 g) were extracted with boiling water
twice (volume over weight values per reﬂux extrac-
tion = 12- and 9-fold, respectively; duration = 1.5 h per
reﬂux extraction); Fructus Ligustri Lucidi (60 g) and Rhi-
zoma Coptidis (20 g) were extracted with 70% ethanol
twice (volume over weight values per reﬂux extrac-
tion = 10- and 8-fold, respectively; duration = 2 h per
reﬂux extraction); Radix Notoginseng (20 g) was extracted
with 50% ethanol twice (volume over weight values per
reﬂux extraction = 10- and 8-fold, respectively; dura-
tion = 2 h per reﬂux extraction). The above three extracts
were combined, ﬁltered by gauzes, and the combined
solution was freeze-dried. Five hundred milligrams of the
freeze-dried powder was extracted with 50 mL methanol
for 20 min under ultrasonics. The methanol extraction was
centrifuged at 15,000 rpm for 15 min at 4 C, and the
supernatant was ﬁltered through a 0.20-lm ﬁlter, the ﬁl-
trate was applied for UPLC analysis. All authentic
Table 3 continued
Type Substituent group Name of constituent MW Observed
CH
GlcO
O
O
C
O
O
O
HO
OH
O
O O
CH
OGlc
H3CO
O
O
OH Oleonuezhenide 1072 In preparation
only
In serum and in preparation: the constituent was observed both in FTZ-treated serum and FTZ preparation, in preparation only: the constituent
was only observed in FTZ preparation, in serum only: the constituent was only observed in FTZ-treated serum
MW molecular weight
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123standards were accurately weighed, and dissolved in
methanol to obtain stock solutions with indicated concen-
trations. All the stock solutions were stored in the refrig-
erator at 4 C until analysis.
Preparation of Serum Samples
Capsule contents of FTZ, originated from the above
extraction, were dispersed with distilled water as stock
Table 4 Structures of the Radix Salvia Miltiorrhiza constituents identiﬁed in FTZ preparation and serum samples from FTZ-treated rats
Type Substituent group Name of constituent MW Observed
HO
HO
R R=CH2CH(OH)COOH Danshensu 198 In preparation only
R=CHO Protocatechuic
aldehyde
138 In preparation only
R=COOH Protocatechuic acid 154 In serum and in preparation
O
OH
OH
OH COOR
COOR
Salvianolic acid B 718 In preparation only
OH
HO
OH
OH
COOR
OH
OH
CH
COOH
R
Salvianolic acid A 494 In preparation only
COOR
HO
OH
Rosmarinic acid 360 In preparation only
O
O
O Dihydrotanshinone I 278 In preparation only
O
O
O Cryptotanshinone 296 In preparation only
O
O
O Tanshinone IIA 294 In preparation only
In serum and in preparation: the constituent was observed both in FTZ-treated serum and FTZ preparation, in preparation only: the constituent
was only observed in FTZ preparation, in serum only: the constituent was only observed in FTZ-treated serum
MW molecular weight
116 X. Zhong et al.
123solution (0.8 g mL
-1). The above suspension was orally
administered to ﬁve rats (2.0 mL/100 g body weight). An
equal volume of distilled water was orally administered to
the other ﬁve rats as control; 30 min after drug adminis-
tration, the animals were anaesthetized by ether inhalation.
The blood was collected from the vena ophthalmica and
then centrifuged at 10,000 rpm for 5 min at 4 C. The
supernatant obtained was frozen immediately and stored at
-80 C before use.
Phosphoric acid (240 lL) was added to 6.0 mL of the
above supernatant and ultrasonicated for 1 min, and vor-
texed for 1 min. The mixed solution was applied to three
pre-activated OASIS HLB solid phase extraction C18
columns (1 cc, 30 mg, Waters Corporation, USA). The
column was washed with 4 mL of water, 2 mL of 100%
methanol and 2 mL of 2% acetic acid glacial–methanol
(1:9). The 100% methanol elutes and 2% acetic acid gla-
cial–methanol (1:9) elutes were collected and dried under
nitrogen gas at 50 C. The residues were re-dissolved in
300 lL of methanol, centrifuged at 15,000 rpm for 15 min
and an aliquot of supernatant was subjected to UPLC
analysis.
Results and Discussions
UPLC–MS/MS Analysis and Identiﬁcation
the Constituents of FTZ
ESI in both negative and positive ion modes was applied to
analyze and identify the constituents in the FTZ. The total
ion current chromatograms at the two ESI modes are
shown in Fig. 1. Fifty-one peaks in FTZ were detected
using UPLC–MS/MS, and 44 constituents were identiﬁed
by comparing their retention behavior, the MS fragments
characteristics to those of authentic standards. The names
and structures of the identiﬁed constituents from Rhizoma
Coptidis, Radix Notoginseng, Fructus Ligustri Lucidi,
Radix Salvia miltiorrhiza, and other three herbs in both
herbal preparation and the serum samples for FTZ-treated
rats are listed in Tables 1, 2, 3, 4 and 5. The identiﬁed
compounds are summarized in Table 6.
In order to obtain MS fragmentation patterns of con-
stituents in FTZ, MS
2 spectra of 19 authentic standards
were recorded by UPLC–MS/MS. Peaks 1, 3, 4, 6, 9, 10,
13, 14, 18, 20, 22, 23, 24, 25, 31, 33, 45, 49 and 51 were
Table 5 Structures of the remaining herbs constituents identiﬁed in FTZ preparation and serum samples from FTZ-treated rats
Type Origin Name of constituent MW Observed
OH
HO OH
OH
Cortex Eucommiae Eucommiol 188 In serum and in
preparation
O
OCH3
OH
HO
OH O
Herbal Cirsii Jeponici and Fructus
Citri Sarcodactylis
Diosmetin 300 In preparation only
O H3CO
OCH3
O Fructus Citri Sarcodactylis 5,7-Dimethoxycoumarin 206 In serum and in
preparation
HO
H3CO
O
O
OH
OCH3
Cortex Eucommiae Pinoresinol 358 In serum and in
preparation
In serum and in preparation: the constituent was observed both in FTZ-treated serum and FTZ preparation; in preparation only: the constituent was
only observed in FTZ preparation; in serum only: the constituent was only observed in FTZ-treated serum
MW molecular weight
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123attributed to danshensu, protocatechuic acid, proto-
catechuic aldehyde, salidroside, rosmarinic acid, salvian-
olic acid B, specnuezhenide, salvianolic acid A,
jatrorrhizine, notoginsenoside R1, palmatine, berberine,
ginsenoside Rg1, ginsenoside Re, 5,7-dimethoxycoumarin,
ginsenoside Rb1, cryptotanshinone, tanshinone IIA and
Fig. 1 UPLC–ESI–MS total ion current chromatograms of FTZ at
the negative ion (a) and positive (b) mode. The numbers appearing in
the circle. These peaks in the circle have similar structures and
retention times, each peak separate incompletely and cannot be
marked clearly, the number in the circle represents four peaks
including
Fig. 2 Total ion current chromatograms at the positive ion mode of rat serum samples collected from control (a) and FTZ-treated (b) group
118 X. Zhong et al.
123oleanolic acid, respectively, by comparing the retention time
and mass data with those of the authentic standards. Other
peaks were identiﬁed, utilizing elemental composition anal-
ysis of theirMS andMS
2 data withsoftware MassLynx from
data and comparing with the literature data as well.
In the negative ion mode, ginsenosides, iridoid/seco-
iridoid glycosides, triterpene acids, and phenolic acids
were observed in the FTZ, which originated from Radix
Notoginseng, Fructus Ligustri Lucidi and Radix Salvia
miltiorrhiza, respectively. Among them, six ginsenosides,
peaks 20, 24, 25, 32, 33, and 38, were identiﬁed as noto-
ginsenoside R1, ginsenoside Rg1, ginsenoside Re, ginse-
noside Rh1/F1 and ginsenoside Rb1 and ginsenoside Rd,
respectively, by comparison with authentic standards and
literature data [17, 18]. The mass spectra of the ginseno-
sides exhibited the molecular ion peaks at [M-H]
- and
[M-H?CH3COOH]
-. In the MS
2 spectra, aglycone ions
m/z 475 and 459 were ﬁnally formed by loss of several
Fig. 3 Total ion current chromatograms at the negative ion mode of rat serum samples collected from control (a) and FTZ-treated (b) group
Fig. 4 Total ion current chromatograms of 9 metabolites identiﬁed from FTZ-treated rat serum samples
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123Table 6 MS data of (?) ESI–MS spectra and (-) ESI–MS spectra, and the identiﬁcation results of the constituents of FTZ preparation and FTZ-
treated rats serum
No. Name Rt (min) MW MS? (m/z)M S - (m/z)
1 Danshensu
a 1.14 198 197[M-H]
-
179[M-H-H2O]
-
135[M-H-H2O-CO2]
-
2(1)
b 10-Hydroxyoleoside
dimethyl ester
2.45 434 452[M?NH4]
? 433[M-H]
-
209[M-H-Glu-CH3CO-H2O]
-
177[M-H-Glu-CH3CO-CH3O-H2O]
-
165[M-H-Glu-2CH3CO-H2O]
-
3 Protocatechuic aldehyde
a 2.62 138 137[M-H]
-
109[M-H–CO]
-
4(2) Salidroside
a 2.99 300 318[M?NH4]
? 299[M-H]
-
179[M-H-C8H8O]
-
119[M-H-C6H12O6]
-
101[M-H-Glu]
-
5(3) Hydroxyl-palmatine 3.85 368 367[M-H]
-
352; 191
6(4) Protocatechuic acid
a 3.89 154 153[M-H]
-
109[M-H-CO2]
-
7 Oleuropeine aglycone 4.36 378 377[M-H]
-
197[M-H-C9H8O4]
-; 153
8(5) Magnoﬂorine 5.04 342 342[M]
?
297[M?H-CH3-
CH3O]
?
282[M?H-2CH3-
CH3O]
?
265[M-CH3-2CH3O]
?
237[M-CH3-2CH3O-
H2O]
?
M1 Jatrorrhizine3-O-b-D-glucuronide 5.77 514 514[M]
?
338[M-GlcUA]
?
9 Rosmarinic acid
a 5.96 360 359[M-H]
-
197[M-H-C9H6O3]
-
179[M-H-C9H6O3-H2O]
-
161[M-H-C9H6O3-2H2O]
-
10 Salvianolic acid B
a 6.52 718 736[M?NH4]
? 717[M-H]
-
519[M-H-C9H10O5]
-
321[M-H-2C9H10O5]
-
339[M-H-C9H10O5-C9H8O4]
-
11(6) Eucommiol 7.19 188 187[M-H]
-; 125; 97
12(7) Thalifendine 7.33 322 322[M]
?
307[M-CH3]
?
279[M-CO-CH3]
?
251[M-2CO-CH3]
?
13 Specnuezhenide
a 7.59 686 704[M?NH4]
? 685[M-H]
-
523[M-H-Glu]
-
453[M-H-Glu-C3H2O2]
-
423[M-H-Glu-C3H2O2-CH2O]
-
299[M-H-Glu-C3H2O2-CH2O-
C7H8O2]
-; 223; 197
120 X. Zhong et al.
123Table 6 continued
No. Name Rt (min) MW MS? (m/z)M S - (m/z)
14 Salvianolic acid A
a 8.03 494 493[M-H]
-
313[M-H-C9H8O4]
-
295[M-H-C9H10O5]
-
185[M-H-C9H10O5-C6H6O2]
-
M2 25-Hydroxy-ginsenoside Rh1/F1 8.23 656 715[M-H?CH3COOH]
-
655[M-H]
-; 493[M-H-Glu]
-
15(8) Columbamine 8.33 338 338[M]
?
322[M-CH4]
?
308[M-2CH3]
?
294[M-CH4-CO]
?
280[M-2CH3-CO]
?
16(9) Epiberberine 8.41 336 336[M]
?
320[M-CH4]
?
294[M-CH4-CO]
?
263[M-CH3-CH2O-
CO]
?
17(10) Coptisine 8.47 320 320[M]
?
292[M-CO]
?
262[M-CO-CH2O]
?
234[M-2CO-CH2O]
?
204[M-2CO-2CH2O]
?
18(11) Jatrorrhizine
a 8.66 338 338[M]
?
322[M-CH4]
?
308[M-2CH3]
?
294[M-CH4-CO]
?
280[M-2CH3-CO]
?
265[M-CH3-CO-
CH2O]
?
250[M-2CH3-CO-
CH2O]
?
M3 25-Hydroxy-ginsenoside Rh1/F1 8.74 656 715[M-H?CH3COOH]
-
655[M-H]
-; 493[M-H-Glu]
-
19 Oleuropein 8.81 540 539[M-H]
-
377[M-H-Glu]
-
307[M-H-Glu-C4H6O]
-
275[M-H-Glu-C4H6O-CH3OH]
-
20(12) Notoginsenoside R1
a 9.17 932 991[M-H?CH3COOH]
-
931[M-H]
-
799[M-H-Xyl]
-
637[M-H-Xyl-Glu]
-
475[M-H-Xyl-2Glu]
-
21(13) Berberrubine 9.49 322 322[M]
?
307[M-CH3]
?
279[M-CO-CH3]
?
251[M-2CO-CH3]
?
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No. Name Rt (min) MW MS? (m/z)M S - (m/z)
22(14) Palmatine
a 9.93 352 352[M]
?
337[M-CH3]
?
336[M-CH4]
?
322[M-2CH3]
?
308[M-CH4-CO]
?
294[M-2CH3-CO]
?
279[M-CH3-CO-
CH2O]
?
23(15) Berberine
a 10.06 336 336[M]
?
321[M-CH3]
?
320[M-CH4]
?
306[M-2CH3]
?
292[M-CH4-CO]
?
278[M-2CH3-CO]
?
262[M-CH4-CO-
CH2O]
?
234[M-CH4-2CO-
CH2O]
?
24(16) Ginsenoside Rg1
a 10.14 800 859[M-H?CH3COOH]
-
637[M-H-Glu]
-; 475[Agl]
-
25 Ginsenoside Re
a 10.39 946 1005[M-H?CH3COOH]
-
945[M-H]
-
799[M-H-Rha]
-
637[M-H-Rha-Glu]
-
475[M-H-Rha-2Glu]
-
26 Diosmetin 10.88 300 299[M-H]
-
284[M-H-CH3]
-
256[M-H-CH3-CO]
-
27 (?)-Pinoresinol-O-b-D-
glucopyranoside
11.27 520 521[M?H]
? 519[M-H]
-
357[M-H-Glu]
-
235[M-H-Glu-CH2O-C6H4O]
-
28(17) Dehydrocorydaline 11.67 366 366[M]
?
350[M-CH4]
?
336[M-2CH3]
?
322[M-CH4-CO]
?
308[M-2CH3-CO]
?
278[M-2CH3-CO-
CH2O]
?
29 Oleonuezhenide 11.74 1072 1071[M-H]
-
771[M-H-C14H20O7]
-
685[M-H-C17H22O10]
-
523[M-H-C17H22O10-Glu]
-
30(18) 13-Methylberberine 11.97 350 350[M]
?
335[M-CH3]
?
334[M-CH4]
?
320[M-2CH3]
?
306[M-CH4-CO]
?
292[M-2CH3-CO]
?
278[M-CH4-2CO]
?
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123Table 6 continued
No. Name Rt (min) MW MS? (m/z)M S - (m/z)
31(19) 5,7-Dimethoxycoumarin
a 12.35 206 207[M?H]
?
192[M?H-CH3]
?
164[M?H-CH3-CO]
?
149[M?H-2CH3-CO]
?
M4 20(S)-Ginsenoside Rh1/
20(R)-Ginsenoside Rh1/
Ginsenoside F1
12.66 638 697[M-H?CH3COOH]
-
441; 423; 405
M5 20(S)/(R)-Protopanaxatriol 13.69 476 477[M?H]
? 493[M-H?H2O]
-
553[M-H?H2O?CH3COOH]
-
M6 20(S)/(R)-Protopanaxatriol 14.02 476 477[M?H]
? 493[M-H?H2O]
-
553[M-H?H2O?CH3COOH]
-
32(20) Ginsenoside F1/
Ginsenoside Rh1
14.14 638 697[M-H?CH3COOH]
-
637[M-H]
-
475[M-H-Glu]
-
33(21) Ginsenoside Rb1
a 14.31 1108 1109[M?H]
?
1126[M?NH4]
?
1091[M?H-H2O]
?
1107[M-H]
-
1167[M-H?CH3COOH]
-
945[M-H-Glu]
-
783[M-H-2Glu]
-
603[M-H-3Glu-H2O]
-; 459[Agl]
-
M7 20(S)-Ginsenoside Rh1/
20(R)-Ginsenoside Rh1/
Ginsenoside F1
14.39 638 697[M-H?CH3COOH]
-
441; 423; 405
34 Coniferin 14.52 342 343[M?H]
?; 295
181[M?H-Glu]
?
164[M?H-Glu-OH]
?;
120
35(22) Not identiﬁed 15.18 532 531[M-H]
-
1063[2M-H]
-
489[M-H-CH2-CO]
-
471[M-H-CH2-CO-H2O]
-
427[M-H-CH2-CO-H2O-CO2]
-
36 Not identiﬁed 15.27 357; 328; 293; 249
37 13-Ethyl-5,6-dihydro-2,3,9,10-
tetramethoxy-
dibenzo[a,g]quinolizinium
15.36 380 398[M?NH4]
?
366[M-CH2]
?
351[M-CH2-CH3]
?
336[M-CH2-2CH3]
?
322[M-CH2-CH4-
CO]
?
38(23) Ginsenoside Rd 15.39 946 947[M?H]
?;
965[M?NH4]
?
945[M-H]
-
1005[M-H?CH3COOH]
-
783[M-H-Glu]
-
621[M-H-2Glu]
-; 459[Agl]
-
M8 Salvianolic acid B sulfates 15.65 798 797[M-H]
-
717[M-H-SO3]
-
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No. Name Rt (min) MW MS? (m/z)M S - (m/z)
39 Dehydrocorybulbine 15.70 352 352[M]
?
337[M-CH3]
?
322[M-2CH3]
?
308[M-CH4-CO]
?
294[M-2CH3-CO]
?
40(24) Pinoresinol 15.71 358 357[M-H]
-
342[M-H-CH3]
-
311[M-H-CH3-2CH3O]
-; 151
41 Not identiﬁed 15.96 259; 244; 201; 189
M9 Ginsenoside Rg3 15.97 784 783[M-H]
-
621[M-H-Glu]
-
459[M-H-2Glu]
-
42 Not identiﬁed 16.14 614; 336; 321
43 Dihydrotanshinone I 16.60 278 279[M?H]
?
261[M?H-H2O]
?
233[M?H-H2O-CO]
?
44 Not identiﬁed 17.19 519 520[M?H]
?
502[M?H-H2O]
?
578[M-H?CH3COOH]
-
45 Cryptotanshinone
a 17.24 296 297[M?H]
?
279[M?H-H2O]
?
268[M?H-C3H6]
?
251[M?H-H2O-CO]
?
227[M?H-C2H5]
?
46(25) Masilinic acid 17.39 472 471[M-H]
-
411[M-2H-CH3-CO2]
-
393[M-2H-CH3-CO2-H2O]
-
47 Not identiﬁed 17.49 496; 478; 184; 104
48 Not identiﬁed 17.64 522; 503; 184; 104
49 Tanshinone IIA
a 17.87 294 295[M?H]
?
277[M?H-H2O]
?
249[M?H-H2O-CO]
?
266[M?H-C2H5]
?
50(26) Pomolic acid acetate 18.19 514 513[M-H]
-
495[M-H-H2O]
-
453[M-H-CH2CO-H2O]
-
51(27) Oleanolic acid
a 18.51 456 455[M-H]
-
407[M-H-HCHO-H2O]
-
391[M-H-HCOOH-H2O]
-
373[M-H-HCOOH-2H2O]
-
MW molecular weight, Glu glucose, Rha rhamnose, Xyl xylose, Agl aglycone, GlcUA glucuronic acid, M metabolites in serum after oral
administration of FTZ
a Structure conﬁrmed by comparison with authentic standards
b Number in parenthesis represents the no. of peak detected in serum after oral administration of FTZ
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123glycosidic units, which were the characteristic ions of
panaxatriols and panaxadiols, respectively [19]. Thus,
these peaks could be identiﬁed as ginsenosides. For exam-
ple, peak 24 showed a molecular ion at m/z 859
[M-H?CH3COOH]
- in MS spectra and exhibited m/z 637
[M–H–Glu]
- and m/z 475 [Agl]
- ions in the MS
2 spectra.
The fragmentation ion at m/z 475 was produced by loss of all
linked glucosidic bonds, which was a characteristic frag-
mentation of protopanaxatriol type ginsenosides [19]. Peak
33 showed a molecular ion at m/z 1107 [M-H]
- in MS
spectra; m/z 945 [M-H-Glu]
-, m/z 783 [M-H-2Glu]
-,
m/z 603 [M-H-3Glu-H2O] and m/z 459 [Agl]
- ions could
be detected in the MS
2 spectra, which exhibited a fragmen-
tation pathway corresponding to the loss of glycosidic units.
The fragmentation ion at m/z 459 corresponds to a charac-
teristic ion of the protopanaxadiol moiety [20].
Iridoid glycosides, secoiridoid glycosides and triterpene
acids are the essential constituents in the Fructus Ligustri
Lucidi extract of FTZ, which include salidroside, oleuro-
peine aglycone, oleuropein, specnuezhenide, masilinic
acid, pomolic acid acetate, oleanolic acid [21, 22]. Peak 13
showed a molecular ion at m/z 685 [M-H]
- in MS spectra
and exhibited m/z 523, 453, 423, 299, 223 and 197 ions in
the MS
2 spectra. By comparison with the authentic
standard, peak 13 was unambiguously identiﬁed as spec-
nuezhenide. The identiﬁcation of peak 19 as oleuropein
was corroborated by detection of the molecular ion at
m/z 539 and its aglycone fragment at m/z 377. The
MS spectrum showed a quasi-molecular ion at m/z 539
[M-H]
- and the fragments were consistent with the fol-
lowing fragmentation pattern: the ion at m/z 377 arose from
the loss of glucose, the ion at m/z 307 was characteristic of
the loss of a C4H6O fragment and the fragment at m/z 275
might derive from the loss of CH3OH from the elenolic
fragment of the molecule [21]. Peak 7 exhibited the
pseudo-molecular ion at m/z 377 in MS and characteristic
ions at m/z 197 and m/z 153 in its MS
2 spectrum, corre-
sponding to the oleuropein aglycone or its isomer. By
retrieving of literature data [22], peak 7 was identiﬁed as
oleuropein aglycone.
Among 51 analytes, there are six phenolic acids and
three diterpenoids originated from Radix Salvia Mil-
tiorrhiza. Phenolic acids could be classiﬁed into monomer
and polymer. Polymers could be composed of one or sev-
eral different monomers such as danshensu, caffeic acid or
others. In the MS
2 spectra of three monomer standards,
including small molecules such as CO2, CO and H2O were
produced in the fragmentation pathways, which indicated
Fig. 5 EIC (a), MS (b) and MS
2 (c) spectra of 25-hydroxy-ginsenoside Rh1/F1 and protopanaxatriol and the possible metabolic
biotransformation pathways (d)
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123the presence of carboxyl, carbonyl or hydroxyl groups [23].
Danshensu showed a [M-H]
- ion at m/z 197, and pro-
duced m/z 179 [M-H-H2O]
- and m/z 135 [M-H-H2O-
CO2]
-. Similar to danshensu, both of the [M-H]
- ions at
m/z 137 of protocatechuic aldehyde and m/z 153 of pro-
tocatechuic acid produced the same ion at m/z 109 corre-
sponding to the loss of CO and CO2, respectively.
As to three polymers, which contained an ester bond
or ester bonds, the predominant fragmentation of their
[M-H]
- ions was the cleavage of the ester bond to lose
danshensu [M-H-198]
- and caffeic acid [M-H-180]
-.
For instance, peak 10 exhibited a quasi-molecular ion
[M-H]
- of m/z 717. Its MS
2 spectra gave rise to prominent
ion at m/z 519 corresponding to the loss of a molecule of
danshensu. Other two fragment ions, [M-H-198-198]
-
ion at m/z 321 and [M-H-198-180]
- ion at m/z 339 cor-
responding to the loss of the second danshensu and the ﬁrst
caffeic acid. These data are consistent with those in the lit-
erature [23]. Therefore, peak 10 was tentatively identiﬁed as
salvianolic acid B. Similarly, peaks 9, 14 were identiﬁed as
rosmarinic acid and salvianolic acid A separately [23, 24].
Rhizoma Coptids alkaloids, which were the most
abundant constituents in the alcohol extra of FTZ, exhib-
ited a special fragmentation pathway in the positive ion
mode. It is well known that loss the neutral species such as
CO, CH3,C H 4 and CH2O were observed in the MS
2
spectra of Rhizoma Coptids alkaloids [9]. Peak 23 showed
a molecular ion at m/z 336 [M]
? in MS spectra, and
exhibited some ions at m/z 320 [M-CH4]
?, 306 [M-
2CH3]
?, 292 [M-CH4-CO]
?, 278 [M-2CH3-CO]
?,
262 [M-CH4-CO-CH2O]
? and 234 [M-CH4-2CO-
CH2O]
? in MS
2 spectra, showing the neutral loss of CO,
CH3,C H 4 and CH2O in the fragmentation pathway. These
data are typical for the Rhizoma Coptids alkaloids in the
present study and consistent with those in the literature [9].
Thus, the compound was identiﬁed as berberine. Similarly,
peaks 8, 12, 15, 16, 17, 18, 21, 22, 28, 30 and 39 were
identiﬁed as magnoﬂorine, thalifendine, columbamine,
epiberberine, coptisine, jatrorrhizine, berberrubine, palm-
atine, dehydrocorydaline, 13-methylberberine and dehyd-
rocorybulbine, respectively [9, 25–27]. Peak 37 showed
the molecular ion at m/z 398 [M?NH4]
? and its product
typical fragments at m/z 366 [M-CH2]
?, 351 [M-CH2-
CH3]
?, 336 [M-CH2-2CH3]
? and 322 [M-CH2-CH4-
CO]
? respectively in the MS
2 spectrum. According to the
literature data [28], we suggested that peak 37 could be
13-ethyl-5,6-dihydro-2,3,9,10-tetramethoxy-
dibenzo[a,g]quinolizinium.
In addition to Rhizoma Coptids alkaloids in positive ion
mode, three diterpenoids (dihydrotanshinone I, cryptotan-
shinone and tanshinone IIA) also exhibited [M?H]
? ions
in positive ion mode. It is well known that hydrogen at C-1
and oxygen at C-11 of tanshinones were the source of the
dissociated H2O and the neutral species such as CO, H2O,
Fig. 5 continued
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123C2H5 and C3H6 were also observed in the MS
2 spectra [29].
Peak 45 showed a molecular ion at m/z 297 [M?H]
? in MS
spectra, and exhibited an ion at m/z 279 [M?H-H2O]
? in
MS
2 spectra, which corresponded to three fragment ions at
m/z 268 [M?H-C3H6]
?, m/z 227 [M?H-C2H5]
? and
m/z 251 [M?H–H2O–CO]
?, showing the neutral loss of
CO, H2O, C2H5 and C3H6 in the fragmentation pathway.
According to these data, peak 45 was tentatively identiﬁed
as cryptotanshinone [30]. Using the same method, peak 43
and peak 49 were identiﬁed as dihydrotanshinone I and
tanshinone IIA by comparison with literature data and
authentic standards [30, 31].
In addition, the molecular ion [M?H]
? of peak 31 was
observed in the MS spectra, which dissociated in MS
2 to
generate several ions at m/z 192, 164, 149 and 121. The
ion at m/z 192 can be attributed to the loss of a methyl
radical from the parent ion, this ion fragmented further
with the loss of CO to give a signal at m/z 164. Sub-
sequent loss of a methyl and a CO group radical to
exhibited ions at m/z 149 and 121, were observed. Com-
paring with the authentic standard and literature data [32],
peak 31 was tentatively identiﬁed as 5, 7–dimethoxy-
coumarin. Peak 34 showed a molecular ion at m/z 343
[M?H]
? in MS spectra, and exhibited four ions at m/z
295, m/z 181 [M?H-Glu]
?, m/z 164 [M?H-Glu-OH]
?
and m/z 120 in MS
2 spectra, showing the loss of glucoside
and hydroxy group in the fragmentation pathway. By
comparison with literature data [33], this component was
ascertained as coniferin.
UPLC–MS/MS Analysis and Identiﬁcation
the Constituents of FTZ in Rat Serum
Analysis of FTZ Constituents in Rat Serum
By comparison with the mass chromatography of FTZ and
the rat serum samples from control group, the MS spectra
for rat serum samples from FTZ-treated group exhibited 27
peaks in common, which demonstrated that the 27 com-
ponents from FTZ were absorbed into the rat blood after
oral administration. In addition, there were another nine
peaks, which were only detected in the dosed serum,
indicating that those components were metabolites of
constituents from FTZ. Ion chromatograms of dosed and
controlled rat serum are shown in Figs. 2, 3 and 4. The MS
spectra and retention behavior of 36 peaks for prototype
components and metabolites are summarized in Table 6.
Analysis of Prototype Constituents of FTZ in Rat Serum
The constituents in rat serum after oral administration of
FTZ were identiﬁed using their retention time and mass
spectra. As a result, peaks 1, 2, 22, 26 and 27 were original
form compounds existing in Fructus Ligustri Lucidi; peaks
Fig. 5 continued
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1233, 5, 7, 8, 9, 10, 11, 13, 14, 15, 17 and 18 came from
Rhizoma Coptidis; peaks 12, 16, 20, 21 and 23 resulted
from Radix Notoginseng; peak 19 and 22 originated from
Fructus Citri Sarcodactylis; peak 6 and 24 came from
Cortex Eucommiae; peak 4 originated from Radix Salvia
Miltiorrhiza. It displayed that most of alkaloids, ginseno-
sides and pentacyclic triterpenes could be unambiguously
detected in their original forms from the rat serum after
FTZ administration.
Analysis of Metabolites of FTZ in Rat Serum
To identify the metabolites accurately, probable structures
were ﬁrst postulated in accordance with the rules and
characteristics of drug metabolism in vivo. In this study, the
constituents of FTZ extract have been identiﬁed. These data
may provide guidance for investigating the metabolites of
FTZ in rat serum. M1 was identiﬁed as the glucuronide
conjugate of alkaloids, jatrorrhizine3-O-b-D-glucuronide,
since it showed the m/z 514 [M]
? in MS spectra, and
exhibited m/z 338 [M-GlcUA]
? in MS
2 spectra, which was
conﬁrmed by comparison with literature data [34]. M2 and
M3 were suspected to be metabolite of ginsenoside Rh1/F1,
both of them showed the same molecular ion at m/z 715
[M-H?CH3COOH]
- in MS spectra, and exhibited product
ions m/z 655 [M-H]
- and m/z 493 [M-H-Glu]
- in MS
2
spectra. By comparison with the literature data [35, 36], this
showed the same fragmentation pathway as the metabolite
of ginsenoside Rh1/F1, so the two constituents were iden-
tiﬁed as the 25-hydroxyl-ginsenoside Rh1/F1. Using the
same method, M5 and M6 were identiﬁed as 20(S)/(R)-
protopanaxatriol because they showed the m/z 477 [M?H]
?
ion in positive ion mode and m/z 493 [M-H?H2O]
- and
m/z 553 [M-H?H2O?CH3COOH]
- ions in negative ion
mode. By comparison with the literature data [36], we
suggested that M5 and M6 may be sapogenin which formed
by loss of all glycosidic units from protopanaxatriol sapo-
nins. The MS and MS
2 spectra and possible metabolic
pathways of 25-hydroxy-ginsenoside Rh1/F1 and proto-
panaxatriol in positive and negative ion mode are shown in
Fig. 5a–d. M4 and M7 showed the molecular ion at m/z
697 [M-H?CH3COOH]
- in MS spectra, and exhibited
m/z 441, 423 and 405 in MS
2 spectra, which hinted those
maybe the metabolites of ginsenoside Re and ginsenoside
Rg1, by losing of one glucose molecular and/or one rham-
nose molecular. By comparison with literature data [35, 37],
we suggested that both of them were 20(S) (R)-ginsenoside
Rh1/ginsenoside F1. M8 showed a molecular ion at m/z 798
[M-H]
- in MS spectra, and exhibited m/z 717 [M-H-
SO3]
- in MS
2 spectra, which was consistent with the
fragmentation of salvianolic acid B sulfates. In accordance
with the literature data on the characteristic of MS/MS [36],
M8 was identiﬁed as salvianolic acid B sulfates. M9 showed
a molecular ion at m/z 783 [M-H]
- in MS spectra, and
exhibited m/z 621 [M-H-Glu]
- and 459 [M-H-2Glu]
-
in MS
2 spectra. The results showed the same fragmentation
pathway as the metabolite of ginsenoside Rb1 and ginse-
noside Rd. By comparison with literature data [38, 39], M9
was suggested as ginsenoside Rg3.
Conclusion
By analyzing the constituents in rat serum of FTZ based on
UPLC–MS technique and serum pharmacochemistry
approach, a method for rapid analysis of the potential
effective constituents in a Chinese Medicine formula FTZ
have been established. In this study, 27 of the prototype
constituents and 9 of the metabolites in rat blood after oral
administration of FTZ were identiﬁed by the UPLC/Q–
TOF system, which enhanced the speed and targeting of
bioactive constituents analysis.
Fig. 5 continued
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123These results indicated that most of the alkaloids, gin-
senosides, and pentacyclic triterpenes could be observed in
rat blood through oral administration of FTZ. Meanwhile
the salvianolic acid analogues could be converted into
metabolites, such as salvianolic acid B sulfates. Our present
work on the comprehensive analysis of the FTZ constituents
in rat serum suggest that the serum pharmacochemistry
study using UPLC–Q–TOF technique offer a rapid and
reliable approach for the identiﬁcation of potential bioactive
compositions for complex herb prescriptions. Systemic
pharmacokinetic investigation of the constituents in rat
serum after oral administration of FTZ is warranted for
better understanding the pharmacokinetic basis of the health
beneﬁts of FTZ.
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